CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Download All
Learn how global experts are leveraging the latest data on CDK4/6 inhibitors in patients with HR+/HER2- EBC. Watch the on-demand webcast from the live webinar, download the slides, and listen to the podcast featuring expert reviews of the most important data on early breast cancer from ESMO Breast 2021.
Javier Cortes, MD, PhD
Stephen R. D. Johnston, MA, FRCP, PhD
Sara Tolaney, MD, MPH

Podcast

In this podcast episode, listen to Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, as they answer clinician questions from a live webinar covering the latest evidence for individualizing treatment of patients with HR-positive, HER2-negative early breast cancer.

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: August 5, 2021

Download this short summary of key takeaways from a podcast on individualizing treatment for patients with HR-positive/HER2-negative early breast cancer.

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: August 17, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings